Reduction in pulmonary fibrosis in vivo by halofuginone

Arnon Nagler*, Natalie Firman, Regina Feferman, Shamay Cotev, Mark Pines, Shmuel Shoshan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Pulmonary fibrosis is a disorder causing a high mortality rate for which therapeutic options are limited. Therefore, the effect of halofuginone, a novel inhibitor of collagen type I synthesis, on bleomycin-induced pulmonary fibrosis was studied in rats. Pulmonary fibrosis was induced by intraperitoneal injections of bleomycin for seven consecutive days, and halofuginone was administered intraperitoneally every second day during the entire experimental period of 42 d. Collagen determination in the lungs and the examination of histologic sections showed that halofuginone significantly reduced fibrosis relative to the untreated control rats. We conclude that halofuginone is a potent in vivo inhibitor of bleomycin-induced pulmonary fibrosis, and that it may potentially be used as a novel therapeutic agent for the treatment of this dysfunction.

Original languageEnglish
Pages (from-to)1082-1086
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number4 I
StatePublished - 1996
Externally publishedYes


Dive into the research topics of 'Reduction in pulmonary fibrosis in vivo by halofuginone'. Together they form a unique fingerprint.

Cite this